COVID-19 and immunomodulation in IBD
Top Cited Papers
Open Access
- 17 April 2020
- Vol. 69 (7), 1335-1342
- https://doi.org/10.1136/gutjnl-2020-321269
Abstract
The current coronavirus pandemic is an ongoing global health crisis due to covid-19, caused by severe acute respiratory syndrome coronavirus 2. Although covid-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. This situation causes various major challenges for gastroenterology. In the context of IBD, several key questions arise. For instance, it is an important question to understand whether patients with IBD (eg, due to intestinal ACE2 expression) might be particularly susceptible to covid-19 and the cytokine release syndrome associated with lung injury and fatal outcomes. Another highly relevant question is how to deal with immunosuppression and immunomodulation during the current pandemic in patients with IBD and whether immunosuppression affects the progress of covid-19. Here, the current understanding of the pathophysiology of covid-19 is reviewed with special reference to immune cell activation. Moreover, the potential implications of these new insights for immunomodulation and biological therapy in IBD are discussed.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (DFG SFB 643; SFB1181; TRR241; FOR2438; KFO257)
This publication has 100 references indexed in Scilit:
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2013
- IL‐23: One cytokine in control of autoimmunityEuropean Journal of Immunology, 2012
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative ColitisThe New England Journal of Medicine, 2012
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2010
- Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2Hypertension, 2010
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's DiseaseGastroenterology, 2008
- A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s diseaseGastroenterology, 2004
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related CarboxypeptidaseJournal of Biological Chemistry, 2002